Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuries

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Sakamoto, Kenichi ^a,b   Kuno, Kyoko ^a   Takemoto, Minoru ^a,b   He, Peng ^a   Ishikawa, Takahiro ^a,b   Onishi, Shunichiro ^a,b   Ishibashi, Ryoichi ^a,b   Okabe, Emiko ^a,b   Shoji, Mayumi ^a,b   Hattori, Akiko ^a,b   Yamaga, Masaya ^a,b   Kobayashi, Kazuki ^a,b   Kawamura, Harukiyo ^a,b   Tokuyama, Hirotake ^a,b   Maezawa, Yoshiro ^a,b   Yokote, Koutaro ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; ANTIINFLAMMATORY AGENT; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; GLOMERULUS; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; INFLAMMATION; KIDNEY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; INFLAMMATION; INTERLEUKIN-6; KIDNEY; KIDNEY GLOMERULUS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PODOCYTES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 84925324900     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/727152     Document Type: Article

References (35)

1. P. Rossing and D. deZeeuw, "Need for better diabetes treatment for improved renal outcome," Kidney International, vol. 79, pp. S28-S32, 2011.
2. B. Braam, J. A. Joles, A. H. Danishwar, and C. A. Gaillard, "Cardiorenal syndrome-current understanding and future perspectives," Nature Reviews Nephrology, vol. 10, no. 1, pp. 48-55, 2014.
3. J. Zhong, X. Rao, and S. Rajagopalan, "An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease," Atherosclerosis, vol. 226, no. 2, pp. 305-314, 2013.
4. B. Hocher, C. Reichetzeder, and M. L. Alter, "Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research," Kidney and Blood Pressure Research, vol. 36, no. 1, pp. 65-84, 2012.
5. K. Kaji, H. Yoshiji, Y. Ikenaka et al., "Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats," Journal of Gastroenterology, vol. 49, no. 3, pp. 481-491, 2014.
6. K. A. Kyle, T. L. Willett, L. L. Baggio, D. J. Drucker, and M. D. Grynpas, "Differential effects of PPAR-γ activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice," Endocrinology, vol. 152, no. 2, pp. 457-467, 2011.
7. C. Pyke, R. S. Heller, R. K. Kirk et al., "GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody," Endocrinology, vol. 155, no. 4, pp. 1280-1290, 2014.
8. W. Jungraithmayr, I. de Meester, V. Matheeussen, L. Baerts, S. Arni, and W. Weder, "CD26/DPP-4 inhibition recruits regenerative stemcells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation," European Journal of Cardio-Thoracic Surgery, vol. 41, no. 5, pp. 1166-1173, 2012.
9. M. L. Alter, I. M. Ott, K. VonWebsky et al., "DPP-4 inhibition on top of angiotensin receptor blockade offers a newtherapeutic approach for diabetic nephropathy," Kidney and Blood Pressure Research, vol. 36, no. 1, pp. 119-130, 2012.
10. M. Haluzík, J. Frolík, and I. Rychlík, "Renal effects of DPP-4 inhibitors: a focus on microalbuminuria," International Journal of Endocrinology, vol. 2013, Article ID 895102, 7 pages, 2013.
11. A. Miyata, A. Arimura, R. R. Dahl et al., "Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells," Biochemical and Biophysical Research Communications, vol. 164, no. 1, pp. 567-574, 1989.
12. D. Vaudry, A. Falluel-Morel, S. Bourgault et al., "Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery," Pharmacological Reviews, vol. 61, no. 3, pp. 283-357, 2009.
13. B. D. Green, N. Irwin, and P. R. Flatt, "Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential," Peptides, vol. 27, no. 6, pp. 1349-1358, 2006.
14. P. Szakaly, P. Kiss, A. Lubics et al., "Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion," Journal of Molecular Neuroscience, vol. 36, no. 1-3, pp. 89-96, 2008.
15. M. Li, S. Balamuthusamy, A. M. Khan, J. L. Maderdrut, E. E. Simon, and V. Batuman, "Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury," Peptides, vol. 31, no. 4, pp. 592-602, 2010.
16. M. Li, J. L. Maderdrut, J. J. L. Lertora, and V. Batuman, "Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study," Peptides, vol. 28, no. 9, pp. 1891-1895, 2007.
17. P. Szakaly, E. Laszlo, K. Kovacs et al., "Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury," Neuropeptides, vol. 45, no. 2, pp. 113-121, 2011.
18. E. Banki, P. Degrell, P. Kiss et al., "Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy," Peptides, vol. 42, pp. 125-130, 2013.
19. T. Sakairi, Y. Abe, P. S. Jat, and J. B. Kopp, "Cell-cell contact regulates gene expression in CDK4-transformed mouse podocytes," The American Journal of Physiology-Renal Physiology, vol. 299, no. 4, pp. F802-F809, 2010.
20. M. Takemoto, N. Asker, H. Gerhardt et al., "A new method for large scale isolation of kidney glomeruli from mice," The American Journal of Pathology, vol. 161, no. 3, pp. 799-805, 2002.
21. M. Li, J. L. Maderdrut, J. J. L. Lertora, A. Arimura, and V. Batuman, "Renoprotection by pituitary adenylate cyclaseactivating polypeptide in multiple myeloma and other kidney diseases," Regulatory Peptides, vol. 145, no. 1-3, pp. 24-32, 2008.
22. M. Li, S. Balamuthusamy, A. M. Khan, J. L. Maderdrut, E. E. Simon, and V. Batuman, "Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure," Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 58-66, 2011.
23. A.-M. Khan, M. Li, E. Brant et al., "Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity," Journal of Investigative Medicine, vol. 59, no. 5, pp. 793-802, 2011.
24. J. C. Reubi, "In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications," Annals of the New York Academy of Sciences, vol. 921, pp. 1-25, 2000.
25. J. Patrakka and K. Tryggvason, "Molecular make-up of the glomerular filtration barrier," Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 164-169, 2010.
26. K. Hoshino, O. Takeuchi, T. Kawai et al., "Cutting edge: Tolllike receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide evidence for TLR4 as the Lps gene product," Journal of Immunology, vol. 162, no. 7, pp. 3749-3752, 1999.
27. M. Lin and S. C. Tang, "Toll-like receptors: sensing and reacting to diabetic injury in the kidney," Nephrology, Dialysis, Transplantation, vol. 29, no. 4, pp. 746-754, 2013.
28. M. C. Banas, B. Banas, K. L. Hudkins et al., "TLR4 links podocytes with the innate immune systemtomediate glomerular injury," Journal of the American Society of Nephrology, vol. 19, no. 4, pp. 704-713, 2008.
29. J. Reiser, G. von Gersdorff, M. Loos et al., "Induction of B7-1 in podocytes is associated with nephrotic syndrome," Journal of Clinical Investigation, vol. 113, no. 10, pp. 1390-1397, 2004.
30. E. Banki, K. Kovacs, D. Nagy et al., "Molecular mechanisms underlying the nephroprotective effects of PACAP in diabetes," Journal of Molecular Neuroscience, vol. 54, no. 3, pp. 300-309, 2014.
31. M. Li, A. M. Khan, J. L. Maderdrut, E. E. Simon, and V. Batuman, "The effect of PACAP38 on MyD88-mediated signal transduction in ischemia-/hypoxia-induced acute kidney injury," The American Journal of Nephrology, vol. 32, no. 6, pp. 522-532, 2010.
32. G. Katsuno, H. K. Takahashi, H. Iwagaki et al., "The effect of ciprofloxacin on CD14 and toll-like receptor-4 expression on human monocytes," Shock, vol. 25, no. 3, pp. 247-253, 2006.
33. 2 mediation in crested newt, Triturus carnifex," Journal of Experimental Zoology, vol. 293, no. 1, pp. 73-80, 2002.
34. B. Ahrén and T. E. Hughes, "Inhibition of dipeptidyl peptidase- 4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclaseactivating polypeptide, and gastrin-releasing peptide in mice," Endocrinology, vol. 146, no. 4, pp. 2055-2059, 2005.
35. L. Zhu, C. Tamvakopoulos, D. Xie et al., "The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1-38)," The Journal of Biological Chemistry, vol. 278, no. 25, pp. 22418-22423, 2003.